JP2025500522A5 - - Google Patents
Info
- Publication number
- JP2025500522A5 JP2025500522A5 JP2024538472A JP2024538472A JP2025500522A5 JP 2025500522 A5 JP2025500522 A5 JP 2025500522A5 JP 2024538472 A JP2024538472 A JP 2024538472A JP 2024538472 A JP2024538472 A JP 2024538472A JP 2025500522 A5 JP2025500522 A5 JP 2025500522A5
- Authority
- JP
- Japan
- Prior art keywords
- subfamily
- tcrαv
- binding moiety
- tcrα
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292859P | 2021-12-22 | 2021-12-22 | |
| US63/292,859 | 2021-12-22 | ||
| PCT/US2022/053705 WO2023122206A2 (en) | 2021-12-22 | 2022-12-21 | Multifuntional molecules binding to tcr and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500522A JP2025500522A (ja) | 2025-01-09 |
| JP2025500522A5 true JP2025500522A5 (enExample) | 2026-01-16 |
Family
ID=86903607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538472A Pending JP2025500522A (ja) | 2021-12-22 | 2022-12-21 | Ｔｃｒに結合する多機能性分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240409636A1 (enExample) |
| EP (1) | EP4453039A4 (enExample) |
| JP (1) | JP2025500522A (enExample) |
| KR (1) | KR20240161975A (enExample) |
| CN (1) | CN118786150A (enExample) |
| AU (1) | AU2022419371A1 (enExample) |
| CA (1) | CA3242160A1 (enExample) |
| GB (1) | GB2631849A (enExample) |
| WO (1) | WO2023122206A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN121487747A (zh) * | 2023-04-27 | 2026-02-06 | 马伦戈治疗公司 | 使用与tcr结合的分子的组合疗法 |
| WO2025049771A1 (en) * | 2023-08-30 | 2025-03-06 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| WO2025147334A1 (en) * | 2024-01-05 | 2025-07-10 | Bright Biologics Llc | ANTI-c-MET/HER2 ANTIBODIES AND USES THEREOF |
| WO2026050517A1 (en) * | 2024-08-28 | 2026-03-05 | Marengo Therapeutics, Inc. | Multispecific molecules binding to tcr and uses thereof |
| WO2026072811A2 (en) * | 2024-09-25 | 2026-04-02 | Marengo Therapeutics, Inc. | Tcr targeting molecules and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053354A2 (en) * | 2000-01-20 | 2001-07-26 | Chiron Corporation | Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules |
| WO2019035938A1 (en) * | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| WO2021138474A2 (en) * | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2021261420A1 (en) * | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
-
2022
- 2022-12-21 EP EP22912450.8A patent/EP4453039A4/en active Pending
- 2022-12-21 CN CN202280092392.1A patent/CN118786150A/zh active Pending
- 2022-12-21 WO PCT/US2022/053705 patent/WO2023122206A2/en not_active Ceased
- 2022-12-21 GB GB2409147.2A patent/GB2631849A/en active Pending
- 2022-12-21 AU AU2022419371A patent/AU2022419371A1/en active Pending
- 2022-12-21 JP JP2024538472A patent/JP2025500522A/ja active Pending
- 2022-12-21 KR KR1020247024329A patent/KR20240161975A/ko active Pending
- 2022-12-21 CA CA3242160A patent/CA3242160A1/en active Pending
-
2024
- 2024-06-21 US US18/749,969 patent/US20240409636A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2631849A (en) | Multifuntional molecules binding to TCR and uses thereof | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| JP7741732B2 (ja) | Ｂｃｍａを標的とする操作された免疫細胞及びその使用 | |
| TWI771678B (zh) | 靶向ｂｃｍａ的工程化免疫細胞及其用途 | |
| JP2022088627A5 (enExample) | ||
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| JP2021530246A5 (enExample) | ||
| Kono et al. | Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer | |
| Wilkie et al. | Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling | |
| GB2623199A (en) | Multifunctional molecules binding to TCR and uses thereof | |
| GB2609554A (en) | Anti-TCR antibody molecules and uses thereof | |
| Zhu et al. | Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F (ab′) 2 for efficient lysis of p185HER2 overexpressing tumor cells | |
| JP2021501570A5 (enExample) | ||
| JP2018064568A (ja) | Ｐｄ−ｌ１によって誘導される免疫寛容の低減 | |
| JP2017531687A5 (enExample) | ||
| Abken et al. | Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity | |
| GB2641599A (en) | Multifunctional molecules binding to TCR and uses thereof | |
| Satta et al. | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors | |
| TW202144434A (zh) | 人源化cd19抗體及其應用 | |
| JP2023522038A5 (enExample) | ||
| Kulemzin et al. | Engineering chimeric antigen receptors | |
| JP2024546999A5 (enExample) | ||
| IL313588A (en) | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer | |
| EP4284824A2 (en) | Chimeric antigen receptors targeting cd20 | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 |